101 related articles for article (PubMed ID: 16101142)
1. Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung.
Blonski K; Schumacher U; Burkholder I; Edler L; Nikbakht H; Boeters I; Peters A; Kugler C; Horny HP; Langer M; Wilhelm-Ogunbiyi K; Witthohn K; Laack E
Anticancer Res; 2005; 25(5):3303-7. PubMed ID: 16101142
[TBL] [Abstract][Full Text] [Related]
2. Impact of mistletoe lectin binding in breast cancer.
Fritz P; Dippon J; Kierschke T; Siegle I; Möhring A; Moisa A; Mürdter TE
Anticancer Res; 2004; 24(2C):1187-92. PubMed ID: 15154645
[TBL] [Abstract][Full Text] [Related]
3. Binding of mistletoe lectins to cutaneous malignant melanoma: implications for prognosis and therapy.
Thies A; Pfüller U; Schachner M; Horny HP; Molls I; Schumacher U
Anticancer Res; 2001; 21(4B):2883-7. PubMed ID: 11712781
[TBL] [Abstract][Full Text] [Related]
4. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours.
Schöffski P; Breidenbach I; Krauter J; Bolte O; Stadler M; Ganser A; Wilhelm-Ogunbiyi K; Lentzen H
Eur J Cancer; 2005 Jul; 41(10):1431-8. PubMed ID: 15913988
[TBL] [Abstract][Full Text] [Related]
5. Lectin histochemistry of metastatic adenocarcinomas of the lung.
Thöm I; Schult-Kronefeld O; Burkholder I; Goern M; Andritzky B; Blonski K; Kugler C; Edler L; Bokemeyer C; Schumacher U; Laack E
Lung Cancer; 2007 Jun; 56(3):391-7. PubMed ID: 17306412
[TBL] [Abstract][Full Text] [Related]
6. Is the binding of mistletoe lectins I and III a useful prognostic indicator in colorectal carcinoma?
Dixon A; Schumacher U; Pfüller U; Taylor I
Eur J Surg Oncol; 1994 Dec; 20(6):648-52. PubMed ID: 7995416
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.
Schöffski P; Riggert S; Fumoleau P; Campone M; Bolte O; Marreaud S; Lacombe D; Baron B; Herold M; Zwierzina H; Wilhelm-Ogunbiyi K; Lentzen H; Twelves C;
Ann Oncol; 2004 Dec; 15(12):1816-24. PubMed ID: 15550588
[TBL] [Abstract][Full Text] [Related]
8. Site-specific mutagenesis of mistletoe lectin: the role of RIP activity in apoptosis.
Langer M; Möckel B; Eck J; Zinke H; Lentzen H
Biochem Biophys Res Commun; 1999 Nov; 264(3):944-8. PubMed ID: 10544035
[TBL] [Abstract][Full Text] [Related]
9. Improvement of an enzyme linked lectin assay to determine recombinant mistletoe lectin I.
Hussein F; Daniels R
J Pharm Biomed Anal; 2007 Jan; 43(2):758-62. PubMed ID: 16971084
[TBL] [Abstract][Full Text] [Related]
10. AB-type lectin (toxin/agglutinin) from mistletoe: differences in affinity of the two galactoside-binding Trp/Tyr-sites and regulation of their functionality by monomer/dimer equilibrium.
Jiménez M; André S; Siebert HC; Gabius HJ; Solís D
Glycobiology; 2006 Oct; 16(10):926-37. PubMed ID: 16774910
[TBL] [Abstract][Full Text] [Related]
11. Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues.
Müthing J; Meisen I; Bulau P; Langer M; Witthohn K; Lentzen H; Neumann U; Peter-Katalinić J
Biochemistry; 2004 Mar; 43(11):2996-3007. PubMed ID: 15023051
[TBL] [Abstract][Full Text] [Related]
12. The preclinical and clinical activity of aviscumine: a potential anticancer drug.
Zwierzina H; Bergmann L; Fiebig H; Aamdal S; Schöffski P; Witthohn K; Lentzen H
Eur J Cancer; 2011 Jul; 47(10):1450-7. PubMed ID: 21482461
[TBL] [Abstract][Full Text] [Related]
13. Coexpression of actin-related protein 2 and Wiskott-Aldrich syndrome family verproline-homologous protein 2 in adenocarcinoma of the lung.
Semba S; Iwaya K; Matsubayashi J; Serizawa H; Kataba H; Hirano T; Kato H; Matsuoka T; Mukai K
Clin Cancer Res; 2006 Apr; 12(8):2449-54. PubMed ID: 16638851
[TBL] [Abstract][Full Text] [Related]
14. In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals.
Klein R; Classen K; Berg PA; Lüdtke R; Werner M; Huber R
Eur J Med Res; 2002 Apr; 7(4):155-63. PubMed ID: 12010650
[TBL] [Abstract][Full Text] [Related]
15. Adaptation and performance of an immuno-PCR assay for the quantification of Aviscumine in patient plasma samples.
Adler M; Langer M; Witthohn K; Wilhelm-Ogunbiyi K; Schöffski P; Fumoleau P; Niemeyer CM
J Pharm Biomed Anal; 2005 Oct; 39(5):972-82. PubMed ID: 15982849
[TBL] [Abstract][Full Text] [Related]
16. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
[TBL] [Abstract][Full Text] [Related]
17. Analysis of tumour necrosis factor alpha-specific, lactose-specific and mistletoe lectin-specific binding sites in human lung carcinomas by labelled ligands.
Kayser K; Gabius HJ; Gabius S; Hagemeyer O
Virchows Arch A Pathol Anat Histopathol; 1992; 421(4):345-9. PubMed ID: 1329310
[TBL] [Abstract][Full Text] [Related]
18. Cellular immunomodulation and safety of standardized aqueous mistletoe extract PS76A2 in tumor patients treated for 48 weeks.
Dohmen W; Breier M; Mengs U
Anticancer Res; 2004; 24(2C):1231-7. PubMed ID: 15154652
[TBL] [Abstract][Full Text] [Related]
19. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.
Takemoto N; Tada M; Hida Y; Asano T; Cheng S; Kuramae T; Hamada J; Miyamoto M; Kondo S; Moriuchi T
Lung Cancer; 2007 Dec; 58(3):376-83. PubMed ID: 17714826
[TBL] [Abstract][Full Text] [Related]
20. Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung.
Enatsu S; Iwasaki A; Shirakusa T; Hamasaki M; Nabeshima K; Iwasaki H; Kuroki M; Kuroki M
Eur J Cardiothorac Surg; 2006 Jun; 29(6):891-5. PubMed ID: 16675263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
